NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
25/06/2024
Voltar para busca
Dado oficial do USPTO
JEPREFI
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
34
Atualização mais recente
25/06/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
23/04/2021
Data de registro
25/06/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
25/06/2024
Última transação
25/06/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
25
Localização do titular
CH
Examinador
MCNAMARA, SHANA
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
NOVARTIS AG
Representantes
Maury M. Tepper, III Tepper & Eyster, PLLC
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
Publicações
Histórico de despachos e eventos da marca no USPTO.
34 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
25/06/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
22/04/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/04/2024
PUBO
PUBLISHED FOR OPPOSITION
09/04/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
20/03/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
20/03/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
20/03/2024
CREV
CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED
06/02/2024
FINA
FINAL DISPOSITION REVIEWED - NO ACTION REQUIRED BY OFFICE
15/03/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
31/01/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/01/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
04/01/2023
CRTP
REG. CANCELLED - RESTORED TO PENDENCY
13/05/2022
APET
ASSIGNED TO PETITION STAFF
11/05/2022
RCII
REQUEST TO CANCEL INADVERTENTLY ISSUED REGISTRATION RECEIVED
06/05/2022
GPAR
GRANT OF PROTECTION CREATED, TO BE SENT TO IB
10/02/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
11/01/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
26/10/2021
PUBO
PUBLISHED FOR OPPOSITION
26/10/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/10/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
17/09/2021
DOCK
ASSIGNED TO EXAMINER
06/09/2021
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
31/07/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
09/07/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/07/2021
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
09/07/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/07/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/07/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
09/07/2021
MAFR
APPLICATION FILING RECEIPT MAILED
29/06/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
25/06/2021
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
24/06/2021
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
17/06/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace JEPREFI ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.